|
Sigma-Aldrich to offer Stemgent’s lentivirus-based gene delivery products for regenerative medicine, stem cell research
December 2009
SHARING OPTIONS:
ST. LOUIS—Sigma-Aldrich announced Nov. 10 that it entered
into an exclusive worldwide distribution agreement with Stemgent Inc. to offer
Stemgent's portfolio of lentivirus-based delivery systems for the generation of
induced pluripotent stem (iPS) cells. The reprogramming technologies offered
under the terms of the agreement involve proprietary viral vectors from
Stemgent, lentivirus technology from Sigma-Aldrich and Dox Inducible expression
from TET Systems. These technologies have been fully validated in Stemgent's laboratories
and are expected to allow researchers to efficiently reprogram mouse and human
cells into iPS cells, enabling researchers to investigate and address the
challenges facing the field of regenerative medicine. Financial details of the
agreement were not disclosed.
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|